Ignite Creation Date:
2025-12-24 @ 2:59 PM
Ignite Modification Date:
2026-01-27 @ 1:07 AM
Study NCT ID:
NCT01459159
Status:
TERMINATED
Last Update Posted:
2013-11-25
First Post:
2011-10-11
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of (Telintra®) in Non-Del(5q) Myelodysplastic Syndrome
Sponsor:
Telik
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Myelodysplastic Syndrome (MDS) | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Hematology | View |
| None | MDS | View |
| None | Myelodysplastic Syndrome | View |
| None | Low risk MDS | View |
| None | Int-1 risk MDS | View |
| None | Transfusion dependence | View |
| None | Telintra | View |
| None | ezatiostat | View |
| None | ezatiostat hydrochloride | View |
| None | TLK199 | View |
| None | Glutathione | View |
| None | Glutathione analog | View |
| None | Glutathione Transferase | View |
| None | Glutathione Transferase P1-1 inhibitor | View |
| None | GST P1-1 inhibitor | View |
| None | Apoptosis | View |
| None | Differentiation | View |
| None | Enzyme inhibitor | View |
| None | non-del (5q) | View |
| None | non-deletion 5q | View |